skip to main content
Resultados 1 2 3 4 5 next page
Mostrar Somente
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Avascular necrosis of the jaws: risk factors in metastatic cancer patients
Material Type:
Artigo
Adicionar ao Meu Espaço

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

Tarassoff, Peter ; Csermak, Katalin

Journal of oral and maxillofacial surgery, 2003-10, Vol.61 (10), p.1238-1239 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

2
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
Material Type:
Artigo
Adicionar ao Meu Espaço

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Rothenberg, M. L. ; Moore, M. J. ; Cripps, M. C. ; Andersen, J. S. ; Portenoy, R. K. ; Burriss, H. A. ; Green, M. R. ; Tarassoff, P. G. ; Brown, T. D. ; Casper, E. S. ; Storniolo, A.-M. ; Von Hoff, D. D.

Annals of oncology, 1996-04, Vol.7 (4), p.347-353 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

3
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
Material Type:
Artigo
Adicionar ao Meu Espaço

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

BURRIS, H. A ; MOORE, M. J ; NELSON, R ; DORR, F. A ; STEPHENS, C. D ; VON HOFF, D. D ; ANDERSEN, J ; GREEN, M. R ; ROTHENBERG, M. L ; MODIANO, M. R ; CRIPPS, M. C ; PORTENOY, R. K ; STORNIOLO, A. M ; TARASSOFF, P

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Sem texto completo

4
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
Material Type:
Artigo
Adicionar ao Meu Espaço

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

CASPER, E. S ; GREEN, M. R ; KELSEN, D. P ; HEELAN, R. T ; BROWN, T. D ; FLOMBAUM, C. D ; TROCHANOWSKI, B ; TARASSOFF, P. G

Investigational new drugs, 1994-01, Vol.12 (1), p.29-34 [Periódico revisado por pares]

Dordrecht: Kluwer

Texto completo disponível

5
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial
Material Type:
Artigo
Adicionar ao Meu Espaço

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Burris, 3rd, H A ; Moore, M J ; Andersen, J ; Green, M R ; Rothenberg, M L ; Modiano, M R ; Cripps, M C ; Portenoy, R K ; Storniolo, A M ; Tarassoff, P ; Nelson, R ; Dorr, F A ; Stephens, C D ; Von Hoff, D D

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5482-5492 [Periódico revisado por pares]

United States

Sem texto completo

6
Osteonecrosis of the Jaw and Bisphosphonates
Material Type:
Artigo
Adicionar ao Meu Espaço

Osteonecrosis of the Jaw and Bisphosphonates

Durie, Brian G M ; Katz, Michael ; Crowley, John

The New England journal of medicine, 2005-07, Vol.353 (1), p.99-102 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

7
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
Material Type:
Artigo
Adicionar ao Meu Espaço

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Abbruzzese, J L ; Grunewald, R ; Weeks, E A ; Gravel, D ; Adams, T ; Nowak, B ; Mineishi, S ; Tarassoff, P ; Satterlee, W ; Raber, M N

Journal of clinical oncology, 1991-03, Vol.9 (3), p.491-498 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Sem texto completo

8
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer
Material Type:
Artigo
Adicionar ao Meu Espaço

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

FOSSELLA, F. V ; LIPPMAN, S. M ; WAUN KI HONG ; SHIN, D. M ; TARASSOFF, P ; CALAYAG-JUNG, M ; PEREZ-SOLER, R ; JIN SOO LEE ; MURPHY, W. K ; GLISSON, B ; RIVERA, E

Journal of clinical oncology, 1997-01, Vol.15 (1), p.310-316 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Sem texto completo

9
Therapeutic Vaccines for Prostate Cancer
Material Type:
Artigo
Adicionar ao Meu Espaço

Therapeutic Vaccines for Prostate Cancer

Tarassoff, Christopher P. ; Arlen, Philip M. ; Gulley, James L.

The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.451-462 [Periódico revisado por pares]

Durham, NC, USA: AlphaMed Press

Texto completo disponível

10
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study
Material Type:
Artigo
Adicionar ao Meu Espaço

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

GRUNEWALD, R ; KANTARJIAN, H ; DU, M ; FAUCHER, K ; TARASSOFF, P ; PLUNKETT, W

Journal of clinical oncology, 1992-03, Vol.10 (3), p.406-413 [Periódico revisado por pares]

PHILADELPHIA: American Society of Clinical Oncology

Sem texto completo

Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (30)
  2. Revistas revisadas por pares (40)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (53)
  2. Resenhas  (8)
  3. Book Chapters  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
  1. Antes de1975  (14)
  2. 1975Até1983  (14)
  3. 1984Até1992  (13)
  4. 1993Até2001  (10)
  5. Após 2001  (12)
  6. Mais opções open sub menu

Buscando em bases de dados remotas. Favor aguardar.